Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-02 mesenchymal stem cells plus in situ-forming alginate gel for lumbar canal stenosis
jRCT2013210076Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of REC-02 in lumbar spinal stenosis (LSS) and lumbar intervertebral disc degenerative disease (LDDD) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety: incidence of adverse events, Effectiveness: pain scores and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
REC-02
03
Conditions
lumbar spinal stenosis (LSS)lumbar intervertebral disc degenerative disease (LDDD)
Beyond the preview
Go deeper on jRCT2013210076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013210076.